Compounds > phenazopyridine

phenazopyridine and furosemide

phenazopyridine has been researched along with furosemide in 8 studies

Research

Studies (8)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (12.50)	18.2507
2000's	5 (62.50)	29.6817
2010's	2 (25.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Gamper, AM; Kroemer, RT; Liedl, KR; Rode, BM; Sotriffer, CA; Varga, JM; Winger, RH	1
Doman, TN; McGovern, SL; Seidler, J; Shoichet, BK	1
Caron, G; Ermondi, G	1
Artursson, P; Bergström, CA; Draheim, R; Holmén, AG; Wassvik, CM	1
González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M	1
Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM	1
Gozalbes, R; Pineda-Lucena, A	1
Bender, A; Czobor, P; Jelinek, B; Málnási-Csizmadia, A; Peragovics, Á; Simon, Z; Tombor, L; Végner, L	1

Other Studies

8 other study(ies) available for phenazopyridine and furosemide

Article	Year
Comparative molecular field analysis of haptens docked to the multispecific antibody IgE(Lb4) Journal of medicinal chemistry, 1996, Sep-27, Volume: 39, Issue:20 Topics: Antibodies, Monoclonal; Antigens; Computer Simulation; Haptens; Hydrogen Bonding; Immunoglobulin E; Models, Molecular; Molecular Structure; Structure-Activity Relationship; Tryptophan; Tyrosine	1996
Identification and prediction of promiscuous aggregating inhibitors among known drugs. Journal of medicinal chemistry, 2003, Oct-09, Volume: 46, Issue:21 Topics: Antifungal Agents; beta-Lactamase Inhibitors; Chemical Phenomena; Chemistry, Physical; Chymotrypsin; Enzyme Inhibitors; Kinetics; Light; Malate Dehydrogenase; Models, Molecular; Molecular Conformation; Scattering, Radiation; Structure-Activity Relationship	2003
Calculating virtual log P in the alkane/water system (log P(N)(alk)) and its derived parameters deltalog P(N)(oct-alk) and log D(pH)(alk). Journal of medicinal chemistry, 2005, May-05, Volume: 48, Issue:9 Topics: 1-Octanol; Alkanes; Hydrogen-Ion Concentration; Least-Squares Analysis; Mathematics; Models, Chemical; Models, Molecular; Solvents; Water	2005
Molecular characteristics for solid-state limited solubility. Journal of medicinal chemistry, 2008, May-22, Volume: 51, Issue:10 Topics: Chemical Phenomena; Chemistry, Physical; Molecular Structure; Multivariate Analysis; Pharmaceutical Preparations; Regression Analysis; Solubility	2008
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors. Journal of medicinal chemistry, 2008, Nov-13, Volume: 51, Issue:21 Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship	2008
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models. Toxicology mechanisms and methods, 2008, Volume: 18, Issue:2-3 Topics:	2008
QSAR-based solubility model for drug-like compounds. Bioorganic & medicinal chemistry, 2010, Oct-01, Volume: 18, Issue:19 Topics: Databases, Factual; Models, Molecular; Pharmaceutical Preparations; Quantitative Structure-Activity Relationship; Solubility; Water	2010
Experimental confirmation of new drug-target interactions predicted by Drug Profile Matching. Journal of medicinal chemistry, 2013, Nov-14, Volume: 56, Issue:21 Topics: Algorithms; Angiotensin-Converting Enzyme Inhibitors; Animals; CHO Cells; Cricetulus; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Humans; Molecular Conformation; Molecular Targeted Therapy; Peptidyl-Dipeptidase A; Receptors, Dopamine D1; Receptors, Dopamine D2; Structure-Activity Relationship; Substrate Specificity	2013